Skip to main content
. 2017 Jul 26;108(9):1843–1849. doi: 10.1111/cas.13309

Figure 2.

Figure 2

(a) Progression‐free survival (PFS) for all study patients with advanced non‐small‐cell lung cancer treated with salazosulfapyridine in combination with cisplatin and pemetrexed (n = 15). (b) Serum level of free CD44 variant (CD44v) before treatment and at day 21 of treatment cycle 1 for 14 of the study patients. **P < 0.01 (paired Student's t‐test).